The Institute for Safe Medication Practices (ISMP) has announced that this year's George DiDomizio Industry Award is being presented to Intelliject, Inc. for pioneering advances in drug/device combination products with the Auvi-Q™ epinephrine auto-injector (also known as Allerject™ in Canada). Auvi-Q is the first auto-injector with audio as well as visual cues for the emergency treatment of life-threatening allergic reactions.
"ISMP does a wonderful job raising awareness and educating both healthcare professionals and the public in order to reduce medication errors. We are honored they are recognizing Auvi-Q and Intelliject," said Mark Licata, Vice President of Industrialization and Quality at Intelliject, and co-inventor of the Auvi-Q.
"With more and more healthcare delivery happening outside the direct supervision of healthcare professionals, there is increasing emphasis on the usability of drug/device combination products," continued Licata. "This award is tangible recognition for the way we have sought to understand and address patient needs."
The George DiDomizio Industry Award is part of the 16th annual ISMP Cheers Awards, which are presented to individuals, organizations, and companies that have set a standard of excellence for others to follow in the prevention of medication errors and adverse drug events. Mr. Licata will accept the award on Intelliject's behalf during a ceremony on December 10 in Orlando, FL.
Auvi-Q (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions. It is the size and shape of a credit card, the thickness of a cell phone and fits comfortably in a pocket or small purse.
During a life-threatening allergic reaction, it talks the user through each step of the injection process. If the patient or caregiver needs more time, it repeats the step-by-step directions. Alternatively, a patient or caregiver can move at his or her own pace by following the printed instructions on the device.
Auvi-Q provides users with audible and visual cues for correct use - including a five-second injection countdown and an alert light to signal when the injection is complete. In addition to being an auto-injector, it features an automatic retractable needle mechanism to help prevent accidental needle sticks.
Available in two different dosages; the Auvi-Q 0.3mg is intended for patients who weigh 66 pounds or more, and Auvi-Q 0.15mg is intended for patients who weigh 33 – 66 pounds. Auvi-Q was not studied in patients weighing less than 33 pounds. Each Auvi-Q pack contains two products - containing one dose of epinephrine each - and a trainer that contains no needle or epinephrine.
Sanofi has exclusive commercial rights to market Auvi-Q and Allerject in US and Canada, respectively. Intelliject retains rights to the product in all other global markets.
Auvi-Q (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions.